MX380749B - Hormonas de crecimiento con eficacia in vivo prolongada. - Google Patents
Hormonas de crecimiento con eficacia in vivo prolongada.Info
- Publication number
- MX380749B MX380749B MX2017002020A MX2017002020A MX380749B MX 380749 B MX380749 B MX 380749B MX 2017002020 A MX2017002020 A MX 2017002020A MX 2017002020 A MX2017002020 A MX 2017002020A MX 380749 B MX380749 B MX 380749B
- Authority
- MX
- Mexico
- Prior art keywords
- prolonged
- vivo efficacy
- growth hormones
- growth hormone
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29730510P | 2010-01-22 | 2010-01-22 | |
| EP10151405 | 2010-01-22 | ||
| PCT/EP2011/050923 WO2011089255A1 (en) | 2010-01-22 | 2011-01-24 | Growth hormones with prolonged in-vivo efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX380749B true MX380749B (es) | 2025-03-12 |
Family
ID=42075933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002020A MX380749B (es) | 2010-01-22 | 2011-01-24 | Hormonas de crecimiento con eficacia in vivo prolongada. |
| MX2012008000A MX345736B (es) | 2010-01-22 | 2011-01-24 | Hormonas de crecimiento con eficacia in vivo prolongada. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008000A MX345736B (es) | 2010-01-22 | 2011-01-24 | Hormonas de crecimiento con eficacia in vivo prolongada. |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US9695226B2 (https=) |
| EP (1) | EP2525834B1 (https=) |
| JP (2) | JP5875527B2 (https=) |
| KR (1) | KR101813595B1 (https=) |
| CN (6) | CN118767116A (https=) |
| AU (1) | AU2011208625C1 (https=) |
| BR (1) | BR112012018116B1 (https=) |
| CA (1) | CA2787890C (https=) |
| FI (1) | FIC20210013I1 (https=) |
| FR (1) | FR21C1029I2 (https=) |
| HU (1) | HUS2100029I1 (https=) |
| IL (1) | IL220605A (https=) |
| MX (2) | MX380749B (https=) |
| NO (1) | NO2021023I1 (https=) |
| PL (1) | PL2525834T3 (https=) |
| RS (1) | RS59459B1 (https=) |
| RU (1) | RU2605627C2 (https=) |
| SI (1) | SI2525834T1 (https=) |
| TW (1) | TWI508737B (https=) |
| WO (1) | WO2011089255A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011015649A1 (en) * | 2009-08-06 | 2011-02-10 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| MX338357B (es) | 2010-01-22 | 2016-04-13 | Novo Nordisk Healthcare Ag | Compuestos estables de la hormona de crecimiento. |
| RS59459B1 (sr) * | 2010-01-22 | 2019-11-29 | Novo Nordisk Healthcare Ag | Hormoni rasta sa produženom in-vivo efikasnošću |
| AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| WO2014060512A1 (en) * | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Fatty acid acylated amino acids for growth hormone delivery |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| WO2015036553A1 (en) | 2013-09-16 | 2015-03-19 | Novo Nordisk Health Care Ag | Thiol functionalized polymers |
| EP3079722B1 (en) * | 2013-12-13 | 2021-03-24 | Novo Nordisk Health Care AG | Method for thioether conjugation of proteins |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| MA41580A (fr) * | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
| CA3183289A1 (en) | 2015-09-08 | 2017-03-16 | Jcr Pharmaceuticals Co., Ltd. | Novel human serum albumin mutant |
| US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| CA2998528A1 (en) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| EP3355931B1 (en) | 2015-10-01 | 2024-06-26 | Novo Nordisk A/S | Protein conjugates |
| JP2017165713A (ja) | 2016-03-14 | 2017-09-21 | Ｊｃｒファーマ株式会社 | 血清アルブミン−２０ｋ成長ホルモン融合タンパク質 |
| US20240228573A9 (en) | 2019-10-17 | 2024-07-11 | Jcr Pharmaceuticals Co., Ltd. | Method for producing fusion protein of serum albumin and growth hormone |
| WO2021085518A1 (ja) | 2019-10-30 | 2021-05-06 | Ｊｃｒファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物 |
| CN115960246B (zh) * | 2021-10-13 | 2026-04-28 | 北京志道生物科技有限公司 | 一种重组环状人生长激素-Fc融合蛋白及其应用 |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
| CN115845079B (zh) * | 2022-11-24 | 2023-07-18 | 武汉禾元生物科技股份有限公司 | 一种重组人血清白蛋白与重组人生长激素的偶联物及其制备方法 |
| JP7823234B2 (ja) * | 2023-05-12 | 2026-03-03 | ノヴォ ノルディスク アー／エス | 長時間作用型成長ホルモン受容体拮抗薬およびその使用 |
| CN118955671A (zh) * | 2023-05-15 | 2024-11-15 | 上海多米瑞生物技术有限公司 | 补体抑制剂及其制备方法和用途 |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504099D0 (en) | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| EP0355460B1 (en) | 1988-08-24 | 2000-12-27 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization |
| US5079230A (en) | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
| EP0397834B1 (en) | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| ATE193541T1 (de) | 1989-03-20 | 2000-06-15 | Gen Hospital Corp | Insulinotropes hormon |
| US5101018A (en) | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| DK0458064T3 (da) | 1990-05-04 | 1998-04-27 | American Cyanamid Co | Stabilisering af somatotropiner ved modificering af cysteinrester |
| US5951972A (en) | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| DK220890D0 (da) | 1990-09-14 | 1990-09-14 | Ole Buchardt | Fremgangsmaade til fremstilling af c-terminalt amiderede peptider |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| JP3267293B2 (ja) | 1990-12-03 | 2002-03-18 | ジェネンテク，インコーポレイテッド | 改変された結合性を有する変異タンパク質の豊富化法 |
| IT1251895B (it) | 1991-09-27 | 1995-05-26 | Eniricerche Spa | Mutanti dell'ormone della crescita umano e loro impiego |
| DE69333718T2 (de) | 1992-01-14 | 2005-12-01 | Ajinomoto Co., Inc. | Gen, das für eine Fisch-Transglutaminase kodiert |
| DK0955062T3 (da) | 1992-07-31 | 2007-09-17 | Genentech Inc | Vandig formulering indeholdende humant væksthormon |
| ZA936811B (en) | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5736356A (en) | 1994-01-28 | 1998-04-07 | Ajinomoto Co., Inc. | Transglutaminase originating from Crassostrea gigas |
| NZ291414A (en) | 1994-08-26 | 1998-05-27 | Novo Nordisk As | Microbial transglutaminases and methods of production using fungi and dna constructs |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| CA2208730A1 (en) | 1995-01-19 | 1996-07-25 | Novo Nordisk A/S | Transglutaminases from oomycetes |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DK0851925T3 (da) | 1995-09-21 | 2005-11-28 | Genentech Inc | Humane Væksthormonvarianter |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| EP0929576A1 (en) | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Glp-2 derivatives |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| CN1231675A (zh) | 1996-09-26 | 1999-10-13 | 味之素株式会社 | 修饰的生理活性蛋白及含有该蛋白的药物组合物 |
| US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
| JPH1156378A (ja) | 1997-06-11 | 1999-03-02 | Nippon Chem Res Kk | 変異型ヒト成長ホルモンとその用途 |
| ES2332931T3 (es) | 1997-06-25 | 2010-02-15 | Merck Serono Sa | Analogos de hormonas glicoproteinicas entrelazadas por disulfuro, su preparacion y uso. |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| JPH1192499A (ja) | 1997-09-22 | 1999-04-06 | Sumitomo Pharmaceut Co Ltd | ヒト成長ホルモン変異体 |
| US6136536A (en) | 1997-10-29 | 2000-10-24 | Genetics Institute, Inc. | Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins |
| EP1056774A1 (en) | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| JP2003522099A (ja) | 1998-02-27 | 2003-07-22 | ノボ ノルディスク アクティーゼルスカブ | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン |
| JP2002506792A (ja) | 1998-02-27 | 2002-03-05 | ノボ ノルディスク アクティーゼルスカブ | Ｎ末端修飾ｇｌｐ−１誘導体 |
| EP1061946B1 (en) | 1998-02-27 | 2004-04-28 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| EP1060192A2 (en) | 1998-02-27 | 2000-12-20 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| US6358705B1 (en) | 1998-07-16 | 2002-03-19 | Novo Nordisk A/S | Method of making proteins in transformed yeast cells |
| CZ295044B6 (cs) | 1998-12-07 | 2005-05-18 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující |
| BR0010750A (pt) | 1999-05-17 | 2002-02-26 | Conjuchem Inc | Peptìdeos insulinotrópicos de longa duração |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| EP1198565A1 (en) | 1999-07-07 | 2002-04-24 | Maxygen Aps | A method for preparing modified polypeptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| WO2001051071A2 (en) | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| CA2739933A1 (en) | 2000-02-11 | 2001-08-16 | Bayer Healthcare Llc | Factor vii or viia-like molecules |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| AU2002219021A1 (en) * | 2001-01-11 | 2002-07-24 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| ES2331909T3 (es) | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| EP1423136A4 (en) | 2001-08-10 | 2007-07-25 | Epix Pharm Inc | POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| EP1444262A2 (en) | 2001-11-12 | 2004-08-11 | University of Wales College of Medicine | Growth hormone variations in humans and their uses |
| WO2003044056A2 (en) | 2001-11-20 | 2003-05-30 | Pharmacia Corporation | Chemically-modified human growth hormone conjugates |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| FR2836382B1 (fr) | 2002-02-28 | 2004-08-13 | Biomerieux Sa | Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic |
| AU2003278807A1 (en) | 2002-03-01 | 2004-08-13 | Bracco International B.V. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| CA2480858A1 (en) | 2002-04-10 | 2003-10-23 | Eli Lilly And Company | Treatment of gastroparesis |
| WO2003093465A1 (en) | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| DE602004025205D1 (de) | 2003-02-19 | 2010-03-11 | Ipsen Pharma | Glp-1-analoga |
| BRPI0409976A (pt) | 2003-05-09 | 2006-05-09 | Novo Nordisk As | composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto |
| WO2005014049A2 (en) | 2003-08-08 | 2005-02-17 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| BR122019021416A2 (https=) * | 2003-09-19 | 2019-12-21 | ||
| RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| JP2008502301A (ja) | 2003-10-10 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | ペプチドの抱合 |
| ATE461217T1 (de) | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
| EP1696962A2 (en) | 2003-12-18 | 2006-09-06 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| US20070105770A1 (en) | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| BRPI0508798A (pt) | 2004-04-07 | 2007-09-04 | Ares Trading Sa | formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento |
| US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| CA2572770A1 (en) | 2004-07-08 | 2006-01-19 | Novo-Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US20090176967A1 (en) | 2004-08-02 | 2009-07-09 | Novo Nordisk Healthcare A/G | Conjugation of FVII |
| WO2006037810A2 (en) | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted glp-1 compounds |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| CN103520735B (zh) | 2004-12-22 | 2015-11-25 | Ambrx公司 | 包含非天然编码的氨基酸的人生长激素配方 |
| US8603972B2 (en) | 2005-03-18 | 2013-12-10 | Novo Nordisk A/S | Extended GLP-1 compounds |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP1863537A2 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| MX2007015676A (es) | 2005-06-15 | 2008-02-20 | Novo Nordisk Healthcare Ag | Conjugacion de la hormona de crecimiento mediada por transglutaminasa. |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| US20090117640A1 (en) | 2005-08-18 | 2009-05-07 | Novo Nordisk Health Care Ag | Transglutaminase Variants with Improved Specificity |
| US8293708B2 (en) | 2005-08-30 | 2012-10-23 | Novo Nordisk Health Care A/G | Liquid formulations N-terminal serine of pegylated growth hormone |
| CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
| AU2007215566A1 (en) | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
| JP5486809B2 (ja) | 2006-02-14 | 2014-05-07 | ノボ ノルディスク ヘルス ケア アーゲー | Ｃ末端におけるポリペプチドの結合 |
| BRPI0713963A2 (pt) * | 2006-07-07 | 2012-11-27 | Novo Nordisk Healthcare Ag | conjugados de proteìna e métodos para sua preparação |
| ES2745411T3 (es) | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
| WO2008020075A1 (en) | 2006-08-18 | 2008-02-21 | Novo Nordisk Health Care Ag | Transglutaminase variants with improved specificity |
| BRPI0716261A2 (pt) | 2006-08-31 | 2013-08-06 | Novartis Ag | composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral |
| US20080095837A1 (en) | 2006-08-31 | 2008-04-24 | Emisphere Technologies, Inc. | Human growth hormone formulations |
| US8383852B2 (en) | 2007-02-16 | 2013-02-26 | Emisphere Technologies, Inc. | Compounds having a cyclic moiety and compositions for delivering active agents |
| GB0716328D0 (en) | 2007-08-21 | 2007-10-03 | Univ Bath | Detection and functionalisation of S-nitrosylated polypeptides |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| WO2010029107A1 (en) | 2008-09-09 | 2010-03-18 | Novo Nordisk Health Care Ag | Growth hormone conjugate with increased stability |
| ES2561208T3 (es) * | 2008-09-12 | 2016-02-25 | Novo Nordisk A/S | Método de acilación de un péptido o una proteína |
| MX2011007736A (es) | 2009-01-22 | 2011-09-06 | Novo Nordisk Healthcare Ag | Compuestos de hormona del crecimiento estables. |
| ES2401965T3 (es) | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
| WO2011015649A1 (en) | 2009-08-06 | 2011-02-10 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| MX338357B (es) | 2010-01-22 | 2016-04-13 | Novo Nordisk Healthcare Ag | Compuestos estables de la hormona de crecimiento. |
| RS59459B1 (sr) | 2010-01-22 | 2019-11-29 | Novo Nordisk Healthcare Ag | Hormoni rasta sa produženom in-vivo efikasnošću |
| ES2582590T3 (es) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Método de purificación |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
-
2011
- 2011-01-24 RS RSP20191198 patent/RS59459B1/sr unknown
- 2011-01-24 RU RU2012134975/10A patent/RU2605627C2/ru active
- 2011-01-24 MX MX2017002020A patent/MX380749B/es unknown
- 2011-01-24 CN CN202410764788.7A patent/CN118767116A/zh active Pending
- 2011-01-24 CN CN202410764782.XA patent/CN118767115A/zh active Pending
- 2011-01-24 EP EP11705470.0A patent/EP2525834B1/en active Active
- 2011-01-24 KR KR1020127021413A patent/KR101813595B1/ko active Active
- 2011-01-24 AU AU2011208625A patent/AU2011208625C1/en active Active
- 2011-01-24 WO PCT/EP2011/050923 patent/WO2011089255A1/en not_active Ceased
- 2011-01-24 CN CN201180015252.6A patent/CN103002918B/zh active Active
- 2011-01-24 CN CN201610206249.7A patent/CN106139158B/zh active Active
- 2011-01-24 BR BR112012018116-5A patent/BR112012018116B1/pt active IP Right Grant
- 2011-01-24 JP JP2012549377A patent/JP5875527B2/ja active Active
- 2011-01-24 CN CN202410764793.8A patent/CN118767117A/zh active Pending
- 2011-01-24 PL PL11705470T patent/PL2525834T3/pl unknown
- 2011-01-24 MX MX2012008000A patent/MX345736B/es active IP Right Grant
- 2011-01-24 TW TW100102456A patent/TWI508737B/zh active
- 2011-01-24 US US13/522,390 patent/US9695226B2/en active Active
- 2011-01-24 SI SI201131785T patent/SI2525834T1/sl unknown
- 2011-01-24 CN CN201180006742.XA patent/CN102834109B/zh not_active Expired - Fee Related
- 2011-01-24 CA CA2787890A patent/CA2787890C/en active Active
-
2012
- 2012-06-24 IL IL220605A patent/IL220605A/en active IP Right Grant
-
2013
- 2013-12-18 US US14/132,919 patent/US8779109B2/en active Active
-
2015
- 2015-10-26 JP JP2015209720A patent/JP2016026204A/ja active Pending
-
2017
- 2017-05-04 US US15/586,960 patent/US20170239362A1/en not_active Abandoned
-
2019
- 2019-03-15 US US16/354,651 patent/US20190203213A1/en not_active Abandoned
- 2019-12-12 US US16/712,651 patent/US20200102568A1/en not_active Abandoned
-
2021
- 2021-05-21 FI FIC20210013C patent/FIC20210013I1/fi unknown
- 2021-05-26 NO NO2021023C patent/NO2021023I1/no unknown
- 2021-07-08 FR FR21C1029C patent/FR21C1029I2/fr active Active
- 2021-08-25 HU HUS2100029C patent/HUS2100029I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380749B (es) | Hormonas de crecimiento con eficacia in vivo prolongada. | |
| UY34347A (es) | Proteínas de función dual para tratar trastornos metabólicos | |
| GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| EA201390796A1 (ru) | Применение ацилированного аналога глюкагона | |
| BR112014032990A2 (pt) | seringa | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| UY34401A (es) | Métodos para el tratamiento de hcv | |
| MX391175B (es) | Macrociclos peptidomimeticos. | |
| IL231614B (en) | Sodium channel regulation by plunc proteins | |
| UY34402A (es) | Métodos para el tratamiento de hcv | |
| CY1118662T1 (el) | Νεες δικυκλικες πυριδινονες | |
| DE112011105572A5 (de) | Therapeutischer Gehtrainer | |
| DK2741763T3 (da) | Sammensætning til kontrolleret ovariestimulering. | |
| MX2011007763A (es) | Metodos y composiciones para tratamiento de cancer de pulmon. | |
| MX359769B (es) | Metodos para descelularizar huesos. | |
| BR112013025866A2 (pt) | formulações com viscosidade reduzida | |
| BR112013033614A2 (pt) | fermentação de pentose por microorganismo recombinante | |
| EP2755544A4 (en) | PROXIMAL HIGH-RESOLUTION ENDOSCOPE | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad | |
| MX2015014470A (es) | Analogos de combretastatina. | |
| CR20160227A (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| BR112014018851A2 (pt) | melhoramento da estabilidade postural administrando droxidopa |